Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD): post hoc analyses of the EMPA-REG OUTCOME trial

被引：0

作者：

Ferreira, J. P. ^{[1
]}

Verma, S. ^{[2
]}

David, F. ^{[3
]}

Ofstad, A. P. ^{[4
]}

Lauer, S. ^{[5
]}

Zwiener, I. ^{[5
]}

George, J. T. ^{[6
]}

Wanner, C. ^{[7
]}

Zinman, B. ^{[8
]}

Inzucchi, S. E. ^{[9
]}

机构：

[1] Univ Lorraine, Inserm 1433, Ctr Invest Clin Plurithemat, Nancy, France

[2] Univ Toronto, Div Cardiac Surg, St Michaels Hosp, Toronto, ON, Canada

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Boehringer Ingelheim Norway KS, Asker, Norway

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Wurzburg Univ Clin, Wurzburg, Germany

[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[9] Yale Univ, Sch Med, New Haven, CT USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

947

引用

页码：S450 / S451

页数：2